Advertisement
Screener

TVARDI THERAPEUTICS, INC. (TVRD) Share-based Payment Arrangement, Expense

2.8 / 5 stars · 68/120 Roast Me

TVARDI THERAPEUTICS, INC. Share-based Payment Arrangement, Expense

TVARDI THERAPEUTICS, INC. (TVRD) reported Share-based Payment Arrangement, Expense of $335.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-14

  • TVARDI THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $335.00K, a 46.57% decline year-over-year.
  • TVARDI THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $370.00K, a 362.50% increase year-over-year.
  • TVARDI THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $353.00K, a 346.84% increase year-over-year.
  • TVARDI THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $339.00K, a 323.75% increase year-over-year.
  • TVARDI THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2025 was $1.40M, a 338.56% increase from fiscal 2024.
  • TVARDI THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2024 was $319.00K.
  • TVARDI THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2019 was $10.30M, a 22.60% increase from fiscal 2018.
  • TVARDI THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2018 was $8.40M, a 32.72% increase from fiscal 2017.
Period endShare-based Payment Arrangement, Expense 3 monthShare-based Payment Arrangement, Expense 6 monthShare-based Payment Arrangement, Expense 9 monthShare-based Payment Arrangement, Expense 12 month
2026-06-30$335.00K
10-Q · filed 2026-08-14
$705.00K
10-Q · filed 2026-08-14
$1.06M
derived: sum of 3 quarters · filed 2026-08-14
$1.40M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31$370.00K
10-Q · filed 2026-05-08
$723.00K
derived: sum of 2 quarters · filed 2026-05-08
$1.06M
derived: sum of 3 quarters · filed 2026-05-08
$1.69M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31$353.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
$692.00K
derived: sum of 2 quarters · filed 2026-03-31
$1.32M
derived: sum of 3 quarters · filed 2026-08-14
$1.40M
10-K · filed 2026-03-31
2025-09-30$339.00K
10-Q · filed 2025-11-13
$966.00K
derived: sum of 2 quarters · filed 2026-08-14
$1.05M
10-Q · filed 2025-11-13
$1.13M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30$627.00K
10-Q · filed 2026-08-14
$707.00K
10-Q · filed 2026-08-14
$786.00K
derived: sum of 3 quarters · filed 2026-08-14
$866.00K
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31$80.00K
10-Q · filed 2026-05-08
$159.00K
derived: sum of 2 quarters · filed 2026-05-08
$239.00K
derived: sum of 3 quarters · filed 2026-05-08
$318.00K
derived: sum of 4 quarters · filed 2026-05-08
2024-12-31$79.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
$159.00K
derived: sum of 2 quarters · filed 2026-03-31
$238.00K
derived: sum of 3 quarters · filed 2026-03-31
$319.00K
10-K · filed 2026-03-31
2024-09-30$80.00K
10-Q · filed 2025-11-13
$159.00K
derived: sum of 2 quarters · filed 2025-11-13
$240.00K
10-Q · filed 2025-11-13
2024-06-30$79.00K
10-Q · filed 2025-08-14
$160.00K
10-Q · filed 2025-08-14
2021-06-30$3.03M
10-Q · filed 2021-08-09
$5.63M
10-Q · filed 2021-08-09
2021-03-31$2.60M
10-Q · filed 2021-05-10
2020-09-30$3.03M
10-Q · filed 2020-11-09
$5.84M
derived: sum of 2 quarters · filed 2021-08-09
$8.52M
10-Q · filed 2020-11-09
$11.19M
derived: sum of 4 quarters · filed 2021-08-09
2020-06-30$2.81M
10-Q · filed 2021-08-09
$5.49M
10-Q · filed 2021-08-09
$8.16M
derived: sum of 3 quarters · filed 2021-08-09
$10.88M
derived: sum of 4 quarters · filed 2021-08-09
2020-03-31$2.68M
10-Q · filed 2021-05-10
$5.35M
derived: sum of 2 quarters · filed 2021-05-10
$8.06M
derived: sum of 3 quarters · filed 2021-05-10
$10.74M
derived: sum of 4 quarters · filed 2021-05-10
2019-12-31$2.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27
$5.38M
derived: sum of 2 quarters · filed 2020-11-09
$8.07M
derived: sum of 3 quarters · filed 2020-11-09
$10.30M
10-K · filed 2020-02-27
2019-09-30$2.71M
10-Q · filed 2020-11-09
$5.39M
derived: sum of 2 quarters · filed 2020-11-09
$7.63M
10-Q · filed 2020-11-09
$10.27M
derived: sum of 4 quarters · filed 2020-11-09
2019-06-30$2.68M
10-Q · filed 2020-08-10
$4.92M
10-Q · filed 2020-08-10
$7.56M
derived: sum of 3 quarters · filed 2020-08-10
$9.38M
derived: sum of 4 quarters · filed 2020-08-10
2019-03-31$2.23M
10-Q · filed 2020-05-11
$4.88M
derived: sum of 2 quarters · filed 2020-05-11
$6.70M
derived: sum of 3 quarters · filed 2020-05-11
$8.76M
derived: sum of 4 quarters · filed 2020-05-11
2018-12-31$2.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27
$4.46M
derived: sum of 2 quarters · filed 2020-02-27
$6.53M
derived: sum of 3 quarters · filed 2020-02-27
$8.40M
10-K · filed 2020-02-27
2018-09-30$1.82M
10-Q · filed 2019-11-05
$3.89M
derived: sum of 2 quarters · filed 2019-11-05
$5.76M
10-Q · filed 2019-11-05
$7.57M
derived: sum of 4 quarters · filed 2020-02-27
2018-06-30$2.07M
10-Q · filed 2019-08-07
$3.94M
10-Q · filed 2019-08-07
$5.75M
derived: sum of 3 quarters · filed 2020-02-27
$7.84M
derived: sum of 4 quarters · filed 2020-02-27
2018-03-31$1.87M
10-Q · filed 2019-05-07
$3.68M
derived: sum of 2 quarters · filed 2020-02-27
$5.78M
derived: sum of 3 quarters · filed 2020-02-27
2017-12-31$1.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27
$3.90M
derived: sum of 2 quarters · filed 2020-02-27
$6.33M
10-K · filed 2020-02-27
2017-09-30$2.09M
10-Q · filed 2018-11-06
$4.52M
10-Q · filed 2018-11-06
2016-12-31$2.80M
10-K · filed 2019-03-12
2014-12-31$340.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27
$562.00K
derived: sum of 2 quarters · filed 2015-03-27
$1.02M
derived: sum of 3 quarters · filed 2015-03-27
$1.37M
10-K · filed 2015-03-27
2014-09-30$222.00K
10-Q · filed 2014-11-10
$678.00K
derived: sum of 2 quarters · filed 2014-11-10
$1.03M
10-Q · filed 2014-11-10
$1.04M
derived: sum of 4 quarters · filed 2015-03-27
2014-06-30$456.00K
10-Q · filed 2014-08-07
$809.00K
10-Q · filed 2014-08-07
$822.00K
derived: sum of 3 quarters · filed 2015-03-27
$881.00K
derived: sum of 4 quarters · filed 2015-03-27
2014-03-31$353.00K
derived: 10-K 12 month − 3 quarters · filed 2015-03-27
$366.00K
derived: sum of 2 quarters · filed 2015-03-27
$425.00K
derived: sum of 3 quarters · filed 2015-03-27
$465.00K
derived: sum of 4 quarters · filed 2015-03-27
2013-12-31$13.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27
$72.00K
derived: sum of 2 quarters · filed 2015-03-27
$112.00K
derived: sum of 3 quarters · filed 2015-03-27
$123.00K
10-K · filed 2015-03-27
2013-09-30$59.00K
10-Q · filed 2014-11-10
$99.00K
derived: sum of 2 quarters · filed 2014-11-10
$110.00K
10-Q · filed 2014-11-10
2013-06-30$40.00K
10-Q · filed 2014-08-07
$51.00K
10-Q · filed 2014-08-07
2012-12-31$61.00K
10-K · filed 2015-03-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14
MUSTANG BIO, INC. (MBIO)United States$0.013B
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36